Back

Breye Therapeutics raises €67.5 million to advance danegaptide into Phase 2

Verifying
  • Breye Therapeutics raised €67.5 million to advance danegaptide into a Phase 2 trial.
  • The randomized NPDR study is scheduled to begin in 2027.
  • Mission BioCapital and Novo Holdings co-led the oversubscribed Series A financing.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.